High-dose proton pump inhibitor versus standard-dose proton pump inhibitor in PPI-based triple therapy for Helicobacter pylori eradication in Lampang hospital: A randomized controlled trial
Phase 1
Completed
- Conditions
- Helicobacter pylori infectionHigh-dose PPI based triple therapy, Helicobacter pylori eradication, Lampang hospital
- Registration Number
- TCTR20210829002
- Lead Sponsor
- ational Research Council of Thailand (NRCT)
- Brief Summary
High-dose PPI based triple therapy achieves higher eradication rate of H. pylori infection than standard-dose PPI based triple therapy for first-line treatment with no difference in side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
1. Adult patients age greater than or equal to 18 years old, 2. H. pylori infection, 3. Did not receive prior eradication therapy
Exclusion Criteria
1. history of gastric cancer or gastrectomy, 2. severe concurrent disease or malignancy, 3. pregnant or lactating, 4. alcohol abuse or drug addiction, 5. previous allergic reaction to study drugs, 6. history of taking PPI, bismuth or antibiotics within 4 weeks, 7. subjects declined to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication rate of H. pylori infection 6 weeks after completion of therapy Urea breath test
- Secondary Outcome Measures
Name Time Method Side effects of study drugs 6 weeks after completion of therapy Patients reported side effects using a questionnaire interview